Live feed06:30:00·38dPRReleasevia QuantisnowCompass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearByQuantisnow·Wall Street's wire, on your screen.CMPS· COMPASS Pathways PlcHealth Care
